Light therapy in the media
Australian medical technology company SYMBYX has completed its first human trial of the use of laser light therapy to reduce the symptoms of Parkinson’s by targeting the gut-brain axis.
EXPLORE OUR TRIALS
May 10, 2023
SYMBYX Biome, an Australian med-tech business, today announced encouraging results from a Sydney Adventist Hospital (commonly known as the San) trial. These results are the six month follow- up results from a triple-blinded, randomised controlled trial run by the San which investigated the efficacy of the SYMBYX Neuro, a new red/infrared light therapy helmet device on People with Parkinson’s (PWP).
March 17, 2023
SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects of a new red/infrared light therapy helmet on patients living with Parkinson’s Disease.
April 22, 2022
SYMBYX, the Australian medical laser company with the world’s first non-pharmaceutical therapy for Parkinson’s, today announced the start of a ground-breaking clinical trial of laser light therapy (photobiomodulation or PBM) on young adults suffering from IBD.
SYMBYX will begin a major clinical trial in Canada using its proprietary treatment system. It's the first Canadian study to examine efficacy of treatment on Parkinson’s symptoms
SYMBYX, an Australian med-tech company developing laser light therapies to reduce Parkinson’s symptoms, said it welcomed the publication of key findings from its Adelaide clinical trial in the leading BMC Neurology Journal.
Australian medical technology company SYMBYX has completed its first human trial of the use of laser light therapy to reduce the symptoms of Parkinson’s by targeting the gut-brain axis.Read Article